A population-based analysis of hematological malignancies from a French-West-Indies cancer registry's data (2009-2018).
Caribbean
Epidemiology
Hematological Malignancies
Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
06 Dec 2023
06 Dec 2023
Historique:
received:
24
05
2023
accepted:
22
11
2023
medline:
11
12
2023
pubmed:
7
12
2023
entrez:
6
12
2023
Statut:
epublish
Résumé
A worldwide increased incidence of HM has been marked in recent decades. Therefore, to update epidemiological characteristics of HM in a French West Indies territory, we have performed analysis through Martinique's population-based cancer registry database. We included cancer case data, from 2009-2018, coded in strict compliance with international standards set by International Agency for Research on Cancer. We calculated standardized incidence rates, cumulative rate (ages 0-74), and temporal trends for cases and deaths using the global population standard, by sex and five age group. Mortality rates were obtained from the French Epidemiology Center on Medical Causes of Death (CépiDc). One thousand forty seven new cases and 674 deaths from HM were recorded, of which 501 MM (47.8%), 377 LMNH (36%), 123 LAM (11.8%), and 46 LH (4.4%) were reported in both sexes. MM is one of the hematological malignancies with the highest incidence in Martinique among men. Temporal trends of incidence rates for all HM decreased overall in both sexes, except for MM in men. There is significant variability in mortality rates for both sexes. In addition, over the period, the temporal trends of mortality rates for all HMs has decreased overall. Gender-specific rates, between 2009 and 2018, showed that all lymphoid HM have a multimodal distribution curve that increased with age. Characteristics of HM in Martinique over the reporting periods differ from mainland France. Higher incidences have been observed, particularly for MM, and non-significant sub-mortality is observed compared to mainland France. Moreover, temporal distribution of mortality and incidence trends had decreased over the reporting periods except for MM. Our results showed similarities with African-Americans groups in United States and in particular an equivalence in the frequency distribution of diagnosed HM. However, SMR remains lower compared to US black ethnic groups. Our results contributed to expanding knowledge on the epidemiology of HM with Caribbean data.
Sections du résumé
BACKGROUND
BACKGROUND
A worldwide increased incidence of HM has been marked in recent decades. Therefore, to update epidemiological characteristics of HM in a French West Indies territory, we have performed analysis through Martinique's population-based cancer registry database.
METHODS
METHODS
We included cancer case data, from 2009-2018, coded in strict compliance with international standards set by International Agency for Research on Cancer. We calculated standardized incidence rates, cumulative rate (ages 0-74), and temporal trends for cases and deaths using the global population standard, by sex and five age group. Mortality rates were obtained from the French Epidemiology Center on Medical Causes of Death (CépiDc).
RESULTS
RESULTS
One thousand forty seven new cases and 674 deaths from HM were recorded, of which 501 MM (47.8%), 377 LMNH (36%), 123 LAM (11.8%), and 46 LH (4.4%) were reported in both sexes. MM is one of the hematological malignancies with the highest incidence in Martinique among men. Temporal trends of incidence rates for all HM decreased overall in both sexes, except for MM in men. There is significant variability in mortality rates for both sexes. In addition, over the period, the temporal trends of mortality rates for all HMs has decreased overall. Gender-specific rates, between 2009 and 2018, showed that all lymphoid HM have a multimodal distribution curve that increased with age.
CONCLUSIONS
CONCLUSIONS
Characteristics of HM in Martinique over the reporting periods differ from mainland France. Higher incidences have been observed, particularly for MM, and non-significant sub-mortality is observed compared to mainland France. Moreover, temporal distribution of mortality and incidence trends had decreased over the reporting periods except for MM. Our results showed similarities with African-Americans groups in United States and in particular an equivalence in the frequency distribution of diagnosed HM. However, SMR remains lower compared to US black ethnic groups. Our results contributed to expanding knowledge on the epidemiology of HM with Caribbean data.
Identifiants
pubmed: 38057723
doi: 10.1186/s12885-023-11666-9
pii: 10.1186/s12885-023-11666-9
pmc: PMC10702113
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1197Informations de copyright
© 2023. The Author(s).
Références
Afr Health Sci. 2007 Sep;7(3):166-75
pubmed: 18052871
Br J Haematol. 2009 Jun;146(1):91-4
pubmed: 19438470
Acta Oncol. 2006;45(3):258-71
pubmed: 16644568
J Hematol Oncol. 2019 Nov 19;12(1):115
pubmed: 31744509
Bone Marrow Transplant. 2013 Sep;48(9):1161-7
pubmed: 23584439
Cytotherapy. 2009;11(1):79-85
pubmed: 19153854
Cancer Epidemiol. 2020 Jun;66:101709
pubmed: 32240959
Leukemia. 2001 May;15(5):828-31
pubmed: 11368445
Rev Epidemiol Sante Publique. 2008 Jun;56(3):159-175
pubmed: 18547762
Cancer Res Treat. 2018 Jan;50(1):222-238
pubmed: 28361523
Cancer Causes Control. 2008 Dec;19(10):1171-81
pubmed: 18543071
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Blood. 2015 Jan 8;125(2):410-2
pubmed: 25573972
J Natl Cancer Inst Monogr. 2014 Aug;2014(48):130-44
pubmed: 25174034
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Front Microbiol. 2012 Sep 10;3:322
pubmed: 22973265
J Glob Oncol. 2019 Nov;5:1-19
pubmed: 31774711
Eur J Haematol. 2015 Jan;94(1):12-22
pubmed: 24797118
Blood. 2013 Aug 8;122(6):981-7
pubmed: 23777769
Hematol Oncol. 2001 Dec;19(4):129-50
pubmed: 11754390
Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1064-77
pubmed: 21493873
Blood. 2010 Dec 16;116(25):5501-6
pubmed: 20823456
Int J Cancer. 2007;120 Suppl 12:1-39
pubmed: 17405121
IARC Sci Publ. 1991;(95):126-58
pubmed: 1894318
Haematologica. 2009 Oct;94(10):1468-9
pubmed: 19794095
J Natl Cancer Inst Monogr. 2014 Aug;2014(48):1-14
pubmed: 25174022
Blood. 2009 Nov 5;114(19):4014-20
pubmed: 19738032
Int J Cancer. 2015 Nov 1;137(9):2060-71
pubmed: 26135522
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593